



Supplementary Figure 3. Kaplan–Meier survival analysis comparing different durations of ATE+BEV treatment in overall patients. (A, B) Survival outcomes for patients treated with ATE+BEV for 3 cycles or fewer. (A) Overall survival; (B) Progression-free survival. (C, D) Survival outcomes for patients treated with ATE+BEV for more than 3 cycles. (C) Overall survival; (D) Progression-free survival. ATE+BEV, atezolizumab plus bevacizumab; PFS, progression-free survival; OS, overall survival.